BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 21621250)

  • 1. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients.
    Paniccia R; Antonucci E; Maggini N; Miranda M; Gori AM; Marcucci R; Giusti B; Balzi D; Prisco D; Abbate R
    Thromb Haemost; 2010 Aug; 104(2):287-92. PubMed ID: 20458439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
    Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
    Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
    El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
    JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?
    Gremmel T; Calatzis A; Steiner S; Kaider A; Seidinger D; Koppensteiner R; Kopp CW; Panzer S
    Platelets; 2010; 21(7):515-21. PubMed ID: 20624009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
    Cuisset T; Frere C; Poyet R; Quilici J; Gaborit B; Bali L; Brissy O; Lambert M; Morange PE; Alessi MC; Bonnet JL
    Arch Cardiovasc Dis; 2010 Jan; 103(1):39-45. PubMed ID: 20142119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity.
    Gremmel T; Kopp CW; Seidinger D; Giurgea GA; Koppensteiner R; Steiner S; Panzer S
    Atherosclerosis; 2009 Dec; 207(2):608-13. PubMed ID: 19616779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
    Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
    Blindt R; Stellbrink K; de Taeye A; Müller R; Kiefer P; Yagmur E; Weber C; Kelm M; Hoffmann R
    Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
    Jover E; Rodríguez JM; Bernal A; Arroyo AB; Iniesta JA; Guiú IS; Martínez C; Vicente V; Lozano ML; Rivera J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):604-11. PubMed ID: 24717421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.